JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.
Ipsen, Genfit’s Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT)
JP Morgan Downgrades ResMed to Neutral
JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.
Related Posts
SVB Leerink Maintains Outperform on Seagen, Lowers Price Target to $152
SVB Leerink analyst Andrew Berens maintains Seagen (NASDAQ:SGEN) with a Outperform and lowers the price target from $159 to $152.
Expert Ratings for Transocean
Over the past 3 months, 5 analysts have published their opinion on Transocean (NYSE:RIG) stock. These analysts are…
